The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...

Inc. (NYSE American: PTN), a small-cap biotech company with a market capitalization of $20.4 million, has announced its corporate milestones for 2025, focusing on the development of treatments for ...

Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...

The FDA has accepted Alvotech (ALVO) and Teva's (TEVA) applications for AVT05, their proposed biosimilar to J&J's ...

Researchers have uncovered differences in how patients with South Asian and white ethnicity present with inflammatory bowel ...

Obesity programs: <li /> Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide ...

MiscellaneousAbivax Publishes 2025 Financial Calendar 28.01.2025 / 08:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax Publishes 2025 Financial Calendar PARIS, ...

Dancing on Ice is in full swing as all of the celebrities taking part have now performed for the judges on the ITV show.

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

After a heartbreakingly traumatic few years of health issues, Louise Thompson exclusively tells Closer what’s next as she ...

EQS-News: ABIVAX / Key word (s): Miscellaneous Abivax Publishes 2025 Financial Calendar 28.01.2025 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement.